✦ LIBER ✦

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative90Y-ibritumomab tiuxetan (Zevalin®)

✍ Scribed by C. Chiesa; F. Botta; A. Coliva; M. Maccauro; L. Devizzi; A. Guidetti; C. Carlo-Stella; E. Seregni; M. A. Gianni; E. Bombardieri

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High activity 90Y-ibritumomab tiuxetan (

✍ Pier F. Ferrucci; Anna Vanazzi; Chiara M. Grana; Marta Cremonesi; Mirco Bartolom 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

High-dose cytosine arabinoside in previo

✍ David J. Adelstein; Hillard M. Lazarus; John D. Hines; Roger H. Herzig 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 399 KB 👁 1 views

Concurrent administration of high-dose c

✍ Ladetto, M; Zallio, F; Vallet, S; Ricca, I; Cuttica, A; Caracciolo, D; Corradini 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 151 KB

Neutropenic infections in 100 patients w

✍ Seropian, S; Nadkarni, R; Jillella, A P; Salloum, E; Burtness, B; Hu, G L; Zelte 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 56 KB

Role of high-dose therapy and initial re

✍ Bouabdallah, R; Coso, D; Costello, R; Bardou, V J; Blaise, D; Xerri, L; Sainty, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 65 KB

Feasibility and toxicity of high-dose ch

✍ Jantunen, E; Mahlamäki, E; Nousiainen, T 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 54 KB